Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport
Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5‐lipoxygenase (5‐LO), 5‐LO‐activating protein (FLAP), leukotriene C4 synthase, and additional downstream enzymes, starting with arachidonic acid substrate. CysLTs produced by macrophages, eo...
Gespeichert in:
Veröffentlicht in: | The FASEB journal 2008-12, Vol.22 (12), p.4352-4362 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4362 |
---|---|
container_issue | 12 |
container_start_page | 4352 |
container_title | The FASEB journal |
container_volume | 22 |
creator | Moos, Michael P. W. Mewburn, Jeffrey D. Kan, Frederick W. K. Ishii, Satoshi Abe, Manabu Sakimura, Kenji Noguchi, Kyoko Shimizu, Takao Funk, Colin D. |
description | Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5‐lipoxygenase (5‐LO), 5‐LO‐activating protein (FLAP), leukotriene C4 synthase, and additional downstream enzymes, starting with arachidonic acid substrate. CysLTs produced by macrophages, eosinophils, mast cells, and other inflammatory cells activate 3 different high‐affinity CysLT receptors: CysLT1R, CysLT2R, and GPR 17. We sought to investigate vascular sites of CysLT2R expression and the role and mechanism of this receptor in mediating vascular permeability events. Vascular expression of CysLT2R was investigated by reporter gene expression in a novel CysLT2R deficient‐LacZ mouse model. CysLT2R was expressed in small, but not large, vessels in mouse brain, bladder, skin, and cremaster muscle. Intravital, in addition to confocal and electron, microscopy investigations using FIT C‐labeled albumin in cremaster postcapillary venule preparations indicated rapid CysLT‐mediated permeability, which was blocked by application of BAY‐u9773, a dual CysLT1R/CysLT2R antagonist or by CysLT2R deficiency. Endothelial human CysLT2R overexpression in mice exacerbated vascular leakage even in the absence of exogenous ligand. The enhanced vascular permeability mediated by CysLT2R takes place via a transendothelial vesicle transport mechanism as opposed to a paracellular route and is controlled via Ca2+ signaling. Our results reveal that CysLT2R can mediate inflammatory reactions in a vascular bed‐specific manner by altering transendothelial vesicle transport‐based vascular permeability.— Moos, M. P. W., Mewburn, J. D., Kan, F. W. K., Ishii, S., Abe, M., Sakimura, K., Noguchi, K., Shimizu, T., Funk, C. D. Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport. FASEB J. 22, 4352–4362 (2008) |
doi_str_mv | 10.1096/fj.08-113274 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69850834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69850834</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3704-aff1e95c1d1a58d0f1d19f251661f1e93242442b9dc6d9624fdb6d3bb45ba7b73</originalsourceid><addsrcrecordid>eNp9kMFO3DAURa2qCKaUXdcoq64aeLYTx1nCqFNASF2Uri0nfhYePEmwnamy4xP6jXxJgzISu67ek-7RWRxCvlC4oFCLS7u9AJlTyllVfCArWnLIhRTwkaxA1iwXgssT8inGLQBQoOKYnFBZVTWXsCKP6ykmdN3kM4_jU5-Cww4zlgVscUh9eH35u0PjdEKT7XVsR69DNmDYoW6cd2nK9k5nKeguYmf69IjeaZ_tMbrW4zIMfUifyZHVPuLZ4Z6S35vvD-ub_P7nj9v11X3e8gqKXFtLsS5baqgupQE7P7VlJRWCvi2cFawoWFObVphasMKaRhjeNEXZ6Kqp-Cn5uniH0D-PGJPaudii97rDfoxK1LIEyYsZ_LaAbehjDGjVENxOh0lRUG9lld0qkGopO-PnB-_YzEHe4UPKGZAL8Md5nP4rU5tf12xzB_Lg_gceE4hv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69850834</pqid></control><display><type>article</type><title>Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Moos, Michael P. W. ; Mewburn, Jeffrey D. ; Kan, Frederick W. K. ; Ishii, Satoshi ; Abe, Manabu ; Sakimura, Kenji ; Noguchi, Kyoko ; Shimizu, Takao ; Funk, Colin D.</creator><creatorcontrib>Moos, Michael P. W. ; Mewburn, Jeffrey D. ; Kan, Frederick W. K. ; Ishii, Satoshi ; Abe, Manabu ; Sakimura, Kenji ; Noguchi, Kyoko ; Shimizu, Takao ; Funk, Colin D.</creatorcontrib><description>Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5‐lipoxygenase (5‐LO), 5‐LO‐activating protein (FLAP), leukotriene C4 synthase, and additional downstream enzymes, starting with arachidonic acid substrate. CysLTs produced by macrophages, eosinophils, mast cells, and other inflammatory cells activate 3 different high‐affinity CysLT receptors: CysLT1R, CysLT2R, and GPR 17. We sought to investigate vascular sites of CysLT2R expression and the role and mechanism of this receptor in mediating vascular permeability events. Vascular expression of CysLT2R was investigated by reporter gene expression in a novel CysLT2R deficient‐LacZ mouse model. CysLT2R was expressed in small, but not large, vessels in mouse brain, bladder, skin, and cremaster muscle. Intravital, in addition to confocal and electron, microscopy investigations using FIT C‐labeled albumin in cremaster postcapillary venule preparations indicated rapid CysLT‐mediated permeability, which was blocked by application of BAY‐u9773, a dual CysLT1R/CysLT2R antagonist or by CysLT2R deficiency. Endothelial human CysLT2R overexpression in mice exacerbated vascular leakage even in the absence of exogenous ligand. The enhanced vascular permeability mediated by CysLT2R takes place via a transendothelial vesicle transport mechanism as opposed to a paracellular route and is controlled via Ca2+ signaling. Our results reveal that CysLT2R can mediate inflammatory reactions in a vascular bed‐specific manner by altering transendothelial vesicle transport‐based vascular permeability.— Moos, M. P. W., Mewburn, J. D., Kan, F. W. K., Ishii, S., Abe, M., Sakimura, K., Noguchi, K., Shimizu, T., Funk, C. D. Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport. FASEB J. 22, 4352–4362 (2008)</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.08-113274</identifier><identifier>PMID: 18779380</identifier><language>eng</language><publisher>United States: Federation of American Societies for Experimental Biology</publisher><subject>Animals ; Biological Transport - genetics ; Biological Transport - physiology ; Calcium Signaling - physiology ; Capillary Permeability - genetics ; Capillary Permeability - physiology ; caveolae ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - metabolism ; Fluorescein-5-isothiocyanate - analogs & derivatives ; Gene Expression ; Humans ; inflammation ; intravital microscopy ; Membrane Microdomains - drug effects ; Mice ; Mice, Transgenic ; Receptors, Leukotriene - biosynthesis ; Receptors, Leukotriene - physiology ; Serum Albumin ; SRS-A - analogs & derivatives ; SRS-A - pharmacology ; transgenic mice</subject><ispartof>The FASEB journal, 2008-12, Vol.22 (12), p.4352-4362</ispartof><rights>FASEB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3704-aff1e95c1d1a58d0f1d19f251661f1e93242442b9dc6d9624fdb6d3bb45ba7b73</citedby><cites>FETCH-LOGICAL-c3704-aff1e95c1d1a58d0f1d19f251661f1e93242442b9dc6d9624fdb6d3bb45ba7b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.08-113274$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.08-113274$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18779380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moos, Michael P. W.</creatorcontrib><creatorcontrib>Mewburn, Jeffrey D.</creatorcontrib><creatorcontrib>Kan, Frederick W. K.</creatorcontrib><creatorcontrib>Ishii, Satoshi</creatorcontrib><creatorcontrib>Abe, Manabu</creatorcontrib><creatorcontrib>Sakimura, Kenji</creatorcontrib><creatorcontrib>Noguchi, Kyoko</creatorcontrib><creatorcontrib>Shimizu, Takao</creatorcontrib><creatorcontrib>Funk, Colin D.</creatorcontrib><title>Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5‐lipoxygenase (5‐LO), 5‐LO‐activating protein (FLAP), leukotriene C4 synthase, and additional downstream enzymes, starting with arachidonic acid substrate. CysLTs produced by macrophages, eosinophils, mast cells, and other inflammatory cells activate 3 different high‐affinity CysLT receptors: CysLT1R, CysLT2R, and GPR 17. We sought to investigate vascular sites of CysLT2R expression and the role and mechanism of this receptor in mediating vascular permeability events. Vascular expression of CysLT2R was investigated by reporter gene expression in a novel CysLT2R deficient‐LacZ mouse model. CysLT2R was expressed in small, but not large, vessels in mouse brain, bladder, skin, and cremaster muscle. Intravital, in addition to confocal and electron, microscopy investigations using FIT C‐labeled albumin in cremaster postcapillary venule preparations indicated rapid CysLT‐mediated permeability, which was blocked by application of BAY‐u9773, a dual CysLT1R/CysLT2R antagonist or by CysLT2R deficiency. Endothelial human CysLT2R overexpression in mice exacerbated vascular leakage even in the absence of exogenous ligand. The enhanced vascular permeability mediated by CysLT2R takes place via a transendothelial vesicle transport mechanism as opposed to a paracellular route and is controlled via Ca2+ signaling. Our results reveal that CysLT2R can mediate inflammatory reactions in a vascular bed‐specific manner by altering transendothelial vesicle transport‐based vascular permeability.— Moos, M. P. W., Mewburn, J. D., Kan, F. W. K., Ishii, S., Abe, M., Sakimura, K., Noguchi, K., Shimizu, T., Funk, C. D. Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport. FASEB J. 22, 4352–4362 (2008)</description><subject>Animals</subject><subject>Biological Transport - genetics</subject><subject>Biological Transport - physiology</subject><subject>Calcium Signaling - physiology</subject><subject>Capillary Permeability - genetics</subject><subject>Capillary Permeability - physiology</subject><subject>caveolae</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Fluorescein-5-isothiocyanate - analogs & derivatives</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>inflammation</subject><subject>intravital microscopy</subject><subject>Membrane Microdomains - drug effects</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Receptors, Leukotriene - biosynthesis</subject><subject>Receptors, Leukotriene - physiology</subject><subject>Serum Albumin</subject><subject>SRS-A - analogs & derivatives</subject><subject>SRS-A - pharmacology</subject><subject>transgenic mice</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFO3DAURa2qCKaUXdcoq64aeLYTx1nCqFNASF2Uri0nfhYePEmwnamy4xP6jXxJgzISu67ek-7RWRxCvlC4oFCLS7u9AJlTyllVfCArWnLIhRTwkaxA1iwXgssT8inGLQBQoOKYnFBZVTWXsCKP6ykmdN3kM4_jU5-Cww4zlgVscUh9eH35u0PjdEKT7XVsR69DNmDYoW6cd2nK9k5nKeguYmf69IjeaZ_tMbrW4zIMfUifyZHVPuLZ4Z6S35vvD-ub_P7nj9v11X3e8gqKXFtLsS5baqgupQE7P7VlJRWCvi2cFawoWFObVphasMKaRhjeNEXZ6Kqp-Cn5uniH0D-PGJPaudii97rDfoxK1LIEyYsZ_LaAbehjDGjVENxOh0lRUG9lld0qkGopO-PnB-_YzEHe4UPKGZAL8Md5nP4rU5tf12xzB_Lg_gceE4hv</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>Moos, Michael P. W.</creator><creator>Mewburn, Jeffrey D.</creator><creator>Kan, Frederick W. K.</creator><creator>Ishii, Satoshi</creator><creator>Abe, Manabu</creator><creator>Sakimura, Kenji</creator><creator>Noguchi, Kyoko</creator><creator>Shimizu, Takao</creator><creator>Funk, Colin D.</creator><general>Federation of American Societies for Experimental Biology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200812</creationdate><title>Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport</title><author>Moos, Michael P. W. ; Mewburn, Jeffrey D. ; Kan, Frederick W. K. ; Ishii, Satoshi ; Abe, Manabu ; Sakimura, Kenji ; Noguchi, Kyoko ; Shimizu, Takao ; Funk, Colin D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3704-aff1e95c1d1a58d0f1d19f251661f1e93242442b9dc6d9624fdb6d3bb45ba7b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Biological Transport - genetics</topic><topic>Biological Transport - physiology</topic><topic>Calcium Signaling - physiology</topic><topic>Capillary Permeability - genetics</topic><topic>Capillary Permeability - physiology</topic><topic>caveolae</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Fluorescein-5-isothiocyanate - analogs & derivatives</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>inflammation</topic><topic>intravital microscopy</topic><topic>Membrane Microdomains - drug effects</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Receptors, Leukotriene - biosynthesis</topic><topic>Receptors, Leukotriene - physiology</topic><topic>Serum Albumin</topic><topic>SRS-A - analogs & derivatives</topic><topic>SRS-A - pharmacology</topic><topic>transgenic mice</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moos, Michael P. W.</creatorcontrib><creatorcontrib>Mewburn, Jeffrey D.</creatorcontrib><creatorcontrib>Kan, Frederick W. K.</creatorcontrib><creatorcontrib>Ishii, Satoshi</creatorcontrib><creatorcontrib>Abe, Manabu</creatorcontrib><creatorcontrib>Sakimura, Kenji</creatorcontrib><creatorcontrib>Noguchi, Kyoko</creatorcontrib><creatorcontrib>Shimizu, Takao</creatorcontrib><creatorcontrib>Funk, Colin D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moos, Michael P. W.</au><au>Mewburn, Jeffrey D.</au><au>Kan, Frederick W. K.</au><au>Ishii, Satoshi</au><au>Abe, Manabu</au><au>Sakimura, Kenji</au><au>Noguchi, Kyoko</au><au>Shimizu, Takao</au><au>Funk, Colin D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2008-12</date><risdate>2008</risdate><volume>22</volume><issue>12</issue><spage>4352</spage><epage>4362</epage><pages>4352-4362</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5‐lipoxygenase (5‐LO), 5‐LO‐activating protein (FLAP), leukotriene C4 synthase, and additional downstream enzymes, starting with arachidonic acid substrate. CysLTs produced by macrophages, eosinophils, mast cells, and other inflammatory cells activate 3 different high‐affinity CysLT receptors: CysLT1R, CysLT2R, and GPR 17. We sought to investigate vascular sites of CysLT2R expression and the role and mechanism of this receptor in mediating vascular permeability events. Vascular expression of CysLT2R was investigated by reporter gene expression in a novel CysLT2R deficient‐LacZ mouse model. CysLT2R was expressed in small, but not large, vessels in mouse brain, bladder, skin, and cremaster muscle. Intravital, in addition to confocal and electron, microscopy investigations using FIT C‐labeled albumin in cremaster postcapillary venule preparations indicated rapid CysLT‐mediated permeability, which was blocked by application of BAY‐u9773, a dual CysLT1R/CysLT2R antagonist or by CysLT2R deficiency. Endothelial human CysLT2R overexpression in mice exacerbated vascular leakage even in the absence of exogenous ligand. The enhanced vascular permeability mediated by CysLT2R takes place via a transendothelial vesicle transport mechanism as opposed to a paracellular route and is controlled via Ca2+ signaling. Our results reveal that CysLT2R can mediate inflammatory reactions in a vascular bed‐specific manner by altering transendothelial vesicle transport‐based vascular permeability.— Moos, M. P. W., Mewburn, J. D., Kan, F. W. K., Ishii, S., Abe, M., Sakimura, K., Noguchi, K., Shimizu, T., Funk, C. D. Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport. FASEB J. 22, 4352–4362 (2008)</abstract><cop>United States</cop><pub>Federation of American Societies for Experimental Biology</pub><pmid>18779380</pmid><doi>10.1096/fj.08-113274</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0892-6638 |
ispartof | The FASEB journal, 2008-12, Vol.22 (12), p.4352-4362 |
issn | 0892-6638 1530-6860 |
language | eng |
recordid | cdi_proquest_miscellaneous_69850834 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
subjects | Animals Biological Transport - genetics Biological Transport - physiology Calcium Signaling - physiology Capillary Permeability - genetics Capillary Permeability - physiology caveolae Endothelium, Vascular - drug effects Endothelium, Vascular - metabolism Fluorescein-5-isothiocyanate - analogs & derivatives Gene Expression Humans inflammation intravital microscopy Membrane Microdomains - drug effects Mice Mice, Transgenic Receptors, Leukotriene - biosynthesis Receptors, Leukotriene - physiology Serum Albumin SRS-A - analogs & derivatives SRS-A - pharmacology transgenic mice |
title | Cysteinyl leukotriene 2 receptor‐mediated vascular permeability via transendothelial vesicle transport |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T05%3A56%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cysteinyl%20leukotriene%202%20receptor%E2%80%90mediated%20vascular%20permeability%20via%20transendothelial%20vesicle%20transport&rft.jtitle=The%20FASEB%20journal&rft.au=Moos,%20Michael%20P.%20W.&rft.date=2008-12&rft.volume=22&rft.issue=12&rft.spage=4352&rft.epage=4362&rft.pages=4352-4362&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.08-113274&rft_dat=%3Cproquest_cross%3E69850834%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69850834&rft_id=info:pmid/18779380&rfr_iscdi=true |